Alnylam Pharmaceuticals (ALNY) Stock: Charts & Financials

Alnylam Pharmaceuticals, Inc.(ALNY)

Biotechnology · Cambridge, MA

$237.10+0.54 (+0.23%)

At close: Aug 28, 2026, 4:00 PM ET

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

2,500 employees

www.alnylam.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yvonne L. Greenstreet

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	4.80B	1.29B	1.17B	1.10B	1.25B	773.69M	594.19M	593.17M	500.92M
Cost of Goods Sold	974.34M	298.26M	211.12M	267.72M	197.23M	142.95M	71.04M	102.82M	85.91M
Gross Profit	3.83B	992.69M	956.05M	829.31M	1.05B	630.74M	523.15M	490.35M	415.01M
Gross Profit Margin	79.7%	76.9%	81.9%	75.6%	84.2%	81.5%	88.0%	82.7%	82.9%
Total Operating Expenses	2.83B	761.25M	687.42M	697.59M	683.81M	646.93M	505.07M	595.51M	491.92M
Research & Development	1.51B	413.13M	364.87M	372.22M	358.81M	323.62M	265.12M	300.17M	270.93M
Selling, General & Administrative	1.32B	347.92M	322.55M	325.37M	322.08M	323.31M	239.95M	295.34M	220.99M
Operating Income (EBIT)	999.78M	231.44M	268.64M	131.72M	367.98M	-16.20M	18.08M	-105.16M	-76.91M
Operating Margin	20.8%	17.9%	23.0%	12.0%	29.5%	-2.1%	3.0%	-17.7%	-15.4%
Income Before Tax (EBT)	799.57M	177.81M	221.65M	161.14M	238.97M	-35.36M	-41.60M	-193.96M	-108.66M
Interest Income	110.05M	28.14M	26.60M	26.63M	28.68M	27.49M	28.67M	31.02M	32.15M
Interest Expense	325.07M	82.05M	69.29M	129.34M	44.40M	40.25M	38.65M	38.97M	34.38M
Other Income/Expense	-200.21M	-53.63M	-46.98M	29.42M	-129.01M	-19.16M	-59.67M	-88.80M	-31.76M
Net Income	807.99M	164.49M	205.99M	186.42M	251.08M	-66.28M	-57.48M	-83.76M	-111.57M
Income Tax Expense	-39.75M	13.31M	-15.66M	-25.28M	-12.12M	30.92M	15.88M	-110.19M	2.91M
Net Profit Margin	16.8%	12.7%	17.6%	17.0%	20.1%	-8.6%	-9.7%	-14.1%	-22.3%
EBITDA	1.05B	244.99M	282.19M	145.22M	381.79M	-2.25M	32.48M	-90.99M	-62.92M
EBITDA Margin	21.9%	19.0%	24.2%	13.2%	30.6%	-0.3%	5.5%	-15.3%	-12.6%
Depreciation & Amortization	54.41M	13.55M	13.55M	13.51M	13.80M	13.94M	14.40M	14.17M	13.98M
EPS Basic	6.10	1.23	1.55	1.41	1.91	-0.51	-0.44	-0.65	-0.87
EPS Diluted	5.92	1.20	1.51	1.37	1.84	-0.51	-0.44	-0.65	-0.87
Shares Outstanding	133.24M	133.24M	132.89M	132.23M	131.45M	129.68M	129.68M	128.59M	128.59M
Diluted Shares Outstanding	138.25M	138.25M	138.23M	136.28M	137.35M	129.68M	129.68M	128.59M	128.59M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

4.80B

1.29B

1.17B

1.10B

1.25B

773.69M

594.19M

593.17M

500.92M

Cost of Goods Sold

974.34M

298.26M

211.12M

267.72M

197.23M

142.95M

71.04M

102.82M

85.91M

Gross Profit

3.83B

992.69M

956.05M

829.31M

1.05B

630.74M

523.15M

490.35M

415.01M

Gross Profit Margin

79.7%

76.9%

81.9%

75.6%

84.2%

81.5%

88.0%

82.7%

82.9%

Total Operating Expenses

2.83B

761.25M

687.42M

697.59M

683.81M

646.93M

505.07M

595.51M

491.92M

Research & Development

1.51B

413.13M

364.87M

372.22M

358.81M

323.62M

265.12M

300.17M

270.93M

Selling, General & Administrative

1.32B

347.92M

322.55M

325.37M

322.08M

323.31M

239.95M

295.34M

220.99M

Operating Income (EBIT)

999.78M

231.44M

268.64M

131.72M

367.98M

-16.20M

18.08M

-105.16M

-76.91M

Operating Margin

20.8%

17.9%

23.0%

12.0%

29.5%

-2.1%

3.0%

-17.7%

-15.4%

Income Before Tax (EBT)

799.57M

177.81M

221.65M

161.14M

238.97M

-35.36M

-41.60M

-193.96M

-108.66M

Interest Income

110.05M

28.14M

26.60M

26.63M

28.68M

27.49M

28.67M

31.02M

32.15M

Interest Expense

325.07M

82.05M

69.29M

129.34M

44.40M

40.25M

38.65M

38.97M

34.38M

Other Income/Expense

-200.21M

-53.63M

-46.98M

29.42M

-129.01M

-19.16M

-59.67M

-88.80M

-31.76M

Net Income

807.99M

164.49M

205.99M

186.42M

251.08M

-66.28M

-57.48M

-83.76M

-111.57M

Income Tax Expense

-39.75M

13.31M

-15.66M

-25.28M

-12.12M

30.92M

15.88M

-110.19M

2.91M

Net Profit Margin

16.8%

12.7%

17.6%

17.0%

20.1%

-8.6%

-9.7%

-14.1%

-22.3%

EBITDA

1.05B

244.99M

282.19M

145.22M

381.79M

-2.25M

32.48M

-90.99M

-62.92M

EBITDA Margin

21.9%

19.0%

24.2%

13.2%

30.6%

-0.3%

5.5%

-15.3%

-12.6%

Depreciation & Amortization

54.41M

13.55M

13.51M

13.80M

13.94M

14.40M

14.17M

13.98M

EPS Basic

6.10

1.23

1.55

1.41

1.91

-0.51

-0.44

-0.65

-0.87

EPS Diluted

5.92

1.20

1.51

1.37

1.84

-0.51

-0.44

-0.65

-0.87

Shares Outstanding

133.24M

132.89M

132.23M

131.45M

129.68M

128.59M

Diluted Shares Outstanding

138.25M

138.23M

136.28M

137.35M

129.68M

128.59M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.71B	2.25B	1.83B	1.04B	844.29M	492.85M	219.75M	74.91M
Cost of Goods Sold	677.17M	323.37M	310.41M	168.82M	140.14M	78.05M	25.06M	1.80M
Gross Profit	3.04B	1.92B	1.52B	868.60M	704.14M	414.80M	194.69M	73.11M
Gross Profit Margin	81.8%	85.6%	83.0%	83.7%	83.4%	84.2%	88.6%	97.6%
Total Operating Expenses	2.54B	2.10B	1.80B	1.65B	1.41B	1.24B	1.13B	887.78M
Research & Development	1.32B	1.13B	1.00B	883.01M	792.16M	654.82M	655.11M	505.42M
Selling, General & Administrative	1.21B	975.53M	795.65M	770.66M	620.64M	588.42M	479.00M	382.36M
Operating Income (EBIT)	501.58M	-176.88M	-282.18M	-785.07M	-708.65M	-828.44M	-939.43M	-814.67M
Operating Margin	13.5%	-7.9%	-15.4%	-75.7%	-83.9%	-168.1%	-427.5%	-1087.6%
Income Before Tax (EBT)	323.15M	-377.38M	-433.52M	-1.13B	-852.14M	-855.60M	-885.25M	-760.67M
Interest Income	111.47M	121.99M	95.56M	24.81M	1.58M	11.81M	33.45M	29.26M
Interest Expense	252.63M	141.86M	121.22M	155.97M	143.02M	84.50M	N/A	N/A
Other Income/Expense	-178.43M	-200.49M	-151.34M	-341.92M	-143.49M	-27.16M	54.18M	54.00M
Net Income	313.75M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M	-886.12M	-761.50M
Income Tax Expense	9.40M	-99.22M	6.72M	4.16M	680K	2.68M	863K	823K
Net Profit Margin	8.4%	-12.4%	-24.1%	-109.0%	-101.0%	-174.1%	-403.2%	-1016.6%
EBITDA	557.24M	-120.22M	-228.12M	-740.60M	-661.09M	-793.67M	-922.26M	-808.24M
EBITDA Margin	15.0%	-5.3%	-12.5%	-71.4%	-78.3%	-161.0%	-419.7%	-1079.0%
Depreciation & Amortization	55.66M	56.67M	54.05M	44.47M	47.57M	34.77M	17.18M	6.43M
EPS Basic	2.39	-2.18	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57
EPS Diluted	2.33	-2.18	-3.52	-9.30	-7.20	-7.46	-8.11	-7.57
Shares Outstanding	131.00M	127.65M	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M
Diluted Shares Outstanding	134.68M	127.65M	124.91M	121.69M	118.45M	114.99M	109.26M	100.59M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

3.71B

2.25B

1.83B

1.04B

844.29M

492.85M

219.75M

74.91M

Cost of Goods Sold

677.17M

323.37M

310.41M

168.82M

140.14M

78.05M

25.06M

1.80M

Gross Profit

3.04B

1.92B

1.52B

868.60M

704.14M

414.80M

194.69M

73.11M

Gross Profit Margin

81.8%

85.6%

83.0%

83.7%

83.4%

84.2%

88.6%

97.6%

Total Operating Expenses

2.54B

2.10B

1.80B

1.65B

1.41B

1.24B

1.13B

887.78M

Research & Development

1.32B

1.13B

1.00B

883.01M

792.16M

654.82M

655.11M

505.42M

Selling, General & Administrative

1.21B

975.53M

795.65M

770.66M

620.64M

588.42M

479.00M

382.36M

Operating Income (EBIT)

501.58M

-176.88M

-282.18M

-785.07M

-708.65M

-828.44M

-939.43M

-814.67M

Operating Margin

13.5%

-7.9%

-15.4%

-75.7%

-83.9%

-168.1%

-427.5%

-1087.6%

Income Before Tax (EBT)

323.15M

-377.38M

-433.52M

-1.13B

-852.14M

-855.60M

-885.25M

-760.67M

Interest Income

111.47M

121.99M

95.56M

24.81M

1.58M

11.81M

33.45M

29.26M

Interest Expense

252.63M

141.86M

121.22M

155.97M

143.02M

84.50M

N/A

Other Income/Expense

-178.43M

-200.49M

-151.34M

-341.92M

-143.49M

-27.16M

54.18M

54.00M

Net Income

313.75M

-278.16M

-440.24M

-1.13B

-852.82M

-858.28M

-886.12M

-761.50M

Income Tax Expense

9.40M

-99.22M

6.72M

4.16M

680K

2.68M

863K

823K

Net Profit Margin

8.4%

-12.4%

-24.1%

-109.0%

-101.0%

-174.1%

-403.2%

-1016.6%

EBITDA

557.24M

-120.22M

-228.12M

-740.60M

-661.09M

-793.67M

-922.26M

-808.24M

EBITDA Margin

15.0%

-5.3%

-12.5%

-71.4%

-78.3%

-161.0%

-419.7%

-1079.0%

Depreciation & Amortization

55.66M

56.67M

54.05M

44.47M

47.57M

34.77M

17.18M

6.43M

EPS Basic

2.39

-2.18

-3.52

-9.30

-7.20

-7.46

-8.11

-7.57

EPS Diluted

2.33

-2.18

-3.52

-9.30

-7.20

-7.46

-8.11

-7.57

Shares Outstanding

131.00M

127.65M

124.91M

121.69M

118.45M

114.99M

109.26M

100.59M

Diluted Shares Outstanding

134.68M